<DOC>
	<DOCNO>NCT00400283</DOCNO>
	<brief_summary>This trial conduct Europe . A seven day dose escalation study subject type 2 diabetes .</brief_summary>
	<brief_title>A Study Looking Into Effect NNC 55-0414 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes Diet treatment least two week Body mass index ( BMI ) 2234 kg/m2 inclusive HbA1C 6.512.0 % inclusive Fasting blood glucose ( FBG ) 7.018.0 mmol/L inclusive Patients negative ( less 70 kU/l ) antibodies glutamic acid decarboxylase ( GAD ) Pharmacological treatment medication pancreatitis Investigator expect interfere blood glucose level History cancer clinically significant cardiovascular respiratory , hepatic , haematological , gastrointestinal , dermatological , venereal , neurological psychiatric disorder judge Investigator Impaired renal function , serum creatinine great 150Âµmol/L Patients , know serum hepatitis carrier Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody , positive result test HIV 1/2 antibody Patients , receive investigational drug four month new chemical entity license product precede start dosing Patients , donate plasma blood past month , excess 500 mL past 12 week Patients significant history alcoholism drug/chemical abuse</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>